Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Does your gut microbiome play a role in therapeutic outcomes?

The role of the gut microbiome and its metabolites in altering the therapeutic outcomes

12 Oct 2023

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

The intricate interactions between gut microbiota and drugs.

11 Oct 2023

Gut health and leukemia: Exploring the crucial connection between diet and microbiota changes

Gut microbiota's role in leukemia treatment responses is explored, with evidence suggesting diet and prebiotics may help manage microbiota alterations in patients. Diet during pregnancy, breastfeeding, and gut microbiota composition all intersect, potentially influencing leukemia risks and treatment outcomes.

8 Oct 2023

New tau PET radiotracer shows promise for early detection of Alzheimer's disease

A new tau PET radiotracer, 18F-SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimer's disease in its earliest stages, according to research published in the September issue of The Journal of Nuclear Medicine.

29 Sep 2023

Improving treatment outcomes for individuals with acute spinal cord injury

A special focus issue of the peer-reviewed Journal of Neurotrauma highlights the latest findings of the North American Clinical Trials Network (NACTN), aimed at improving outcomes for individuals with acute spinal cord injury (SCI).

27 Sep 2023

Promising potential of probiotics and their byproducts for targeting antibiotic-resistant bacteria

The use of probiotics and antimicrobial peptides (AMPs) against multi-drug-resistant (MDR) bacteria.

27 Sep 2023

Experts call for changes to how drugs are tested and labeled for people with obesity

A new opinion piece published in Health Affairs Forefront raises questions around current approaches to assess drug safety and effectiveness in people with obesity.

5 Sep 2023

Engineered ACE2 decoy shows promise as COVID-19 treatment

Researchers from Japan demonstrated that an engineered angiotensin-converting enzyme 2 (ACE2) receptor, which showed the potential to remarkably reduce the emergence of resistant virus strains, could successfully exert its therapeutic effect in primates, which may open avenues for the application of the technology for the treatment of humans.

30 Aug 2023

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.

30 Aug 2023

Intellegens and CPI awarded £1.6m Innovate UK grant to advance manufacture of oligonucleotide therapeutics with machine learning

Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, today announced that it has secured a £1.6m grant from Innovate UK, part of UK Research and Innovation (UKRI), to apply ML in the emerging field of oligonucleotide therapies.

30 Aug 2023

Study shows that CD98hc can be targeted to deliver biotherapeutics in brain

Researchers engineered and characterized a blood-brain barrier transport vehicle targeting the CD98 heavy chain of heterodimeric amino acid transporters.

24 Aug 2023

Illustrating the safety of a new drug treatment designed for spinal cord injury

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants.

11 Aug 2023

Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

A new study of mice and lab-grown human colon "organoids" indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.

10 Aug 2023

Duke researchers develop potent antibiotic against drug-resistant superbugs

A scientific journey decades in the making at Duke University has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, the culprits in many urinary tract infections (UTIs).

9 Aug 2023

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

31 Jul 2023

Embracing nature's medicine: exploring medicinal plants for diabetes treatment

Researchers described 20 medicinal plants, their bioactive phytochemical components, therapeutic potential, modes of action, and prospects and ability to combat diabetes mellitus.

27 Jul 2023

A novel pharmacology modeling approach to monitor acute lymphoblastic leukemia treatment

This research paper published in Scientific Reports developed pharmacokinetic (PK) pharmacodynamic (PD) models of maintenance therapy for childhood acute lymphoblastic leukemia (ALL).

26 Jul 2023

Understanding the mechanisms behind rising antifungal drug resistance

In a recent study, researchers addressed the issue of the rise of antifungal drugs-resistant infections and the advent of multidrug-resistant fungal pathogens.

19 Jul 2023

An evaluation of the main nanotechnology approaches to improve the therapeutic potential of polyphenols against cancer

Researchers comprehensively evaluated all nanotechnology-based approaches.

18 Jul 2023

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

5 Jul 2023

Pharmacokinetics News and Research

Further Reading

Does your gut microbiome play a role in therapeutic outcomes?

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

Gut health and leukemia: Exploring the crucial connection between diet and microbiota changes

New tau PET radiotracer shows promise for early detection of Alzheimer's disease

Improving treatment outcomes for individuals with acute spinal cord injury

Promising potential of probiotics and their byproducts for targeting antibiotic-resistant bacteria

Experts call for changes to how drugs are tested and labeled for people with obesity

Engineered ACE2 decoy shows promise as COVID-19 treatment

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Intellegens and CPI awarded £1.6m Innovate UK grant to advance manufacture of oligonucleotide therapeutics with machine learning

Study shows that CD98hc can be targeted to deliver biotherapeutics in brain

Illustrating the safety of a new drug treatment designed for spinal cord injury

Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

Duke researchers develop potent antibiotic against drug-resistant superbugs

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Embracing nature's medicine: exploring medicinal plants for diabetes treatment

A novel pharmacology modeling approach to monitor acute lymphoblastic leukemia treatment

Understanding the mechanisms behind rising antifungal drug resistance

An evaluation of the main nanotechnology approaches to improve the therapeutic potential of polyphenols against cancer

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News